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Early lifeFibroblast growth factor-23 (FGF23), a phosphate(Phos)-regulating hormone, is abnormally elevated in
hypophosphataemic syndromes and an elevated FGF23 is a predictor of mortality in kidney disease. Recent ﬁnd-
ings suggest iron deﬁciency as a potential mediator of FGF23 expression andmurine studies have shown in utero
effects of maternal iron deﬁciency on offspring FGF23 and phosphate metabolism.
Our aim was to investigate the impact of maternal iron status on infant FGF23 and mineral metabolites over the
ﬁrst 2 years of life. Infants born tomotherswith normal (NI n= 25,) and low (LI n= 25) iron status during preg-
nancy, fromamother-infant trial (ISRCTN49285450) in rural Gambia,WestAfrica, had blood and plasma samples
analysed at 12, 24, 52, 78 and 104 weeks (wk) of age.
Circulating intact-FGF23 (I-FGF23), Phos, total alkaline phosphatase (TALP) and haemoglobin (Hb) decreased
and estimated glomerular ﬁltration rate increased over time [all P ≤ 0.0001)]. C-terminal-FGF23 (C-FGF23) and
TALP were signiﬁcantly higher in LI compared with NI, from 52 wk for C-FGF23 [Beta coefﬁcient (SE) 18.1
(0.04) %, P=0.04] and from 24wk for TALP [44.7 (29.6) U/L, P=0.04]. Infant Hbwas the strongest negative pre-
dictor of C-FGF23 concentration [−21% (4%) RU/mL, P ≤ 0.0001], Phos was the strongest positive predictor of I-
FGF23 [32.0(3.9) pg/mL, P ≤ 0.0001] and I-FGF23 did not predict C-FGF23 over time [−0.5% (0.5%), P= 0.3].
In conclusion, this study suggests that poor maternal iron status is associated with a higher infant C-FGF23 and
TALP but similar I-FGF23 concentrations in infants and young children. These ﬁndings further highlight the likely
public health importance of preventing iron deﬁciency during pregnancy.Whether or not childrenwho are born
to iron deﬁcient mothers have persistently high concentrations of these metabolites and are more likely to be at
risk of impaired bone development and pre-disposed to rickets requires further research.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
An elevated concentration of circulating ﬁbroblast growth factor-23
(FGF23) has been shown to be involved in an ever growing set of
diseases since its discovery as the cause of certain forms of bone
mineralisation disorders such as hereditary hypophosphataemic rickets
[1]. These include renal disease and arterial calciﬁcation, and an ele-
vated FGF23 concentration is a predictor of mortality in these pa-
tients [2]. FGF23, mainly expressed in osteocytes, is primarily a
regulator of phosphate (Phos) homeostasis, acting predominantly at
the kidney to increase Phos excretion by regulating sodium-phosphate
co-transporters, but it also regulates CYP27B1 and CYP24A1 enzyme
activity and thus has effects on vitamin D metabolism [3,4].Research, Elsie Widdowson
(V.S. Braithwaite).
. This is an open access article underThe regulatory mechanisms of FGF23 gene expression and subse-
quent protein processing in the osteocyte are unclear but a role for
iron in FGF23 regulation has been identiﬁed. A growing body of evi-
dence has shown inverse associations between markers of iron status
with FGF23 concentration in animals [5,6] and human studies in Africa
[7–10], North America [11] and Poland [12]. Amurine study has indicat-
ed that maternal iron status during pregnancy inﬂuences FGF23 and
Phos regulation in infancy [6]. The study showed that pups born to
iron deﬁcient dams had signiﬁcantly higher serum C-terminal and
Intact- FGF23 concentrations and correspondingly lower Phos and
1,25-dihydroxyvitamin D (1,25(OH)2D) concentrations compared
with pups born to iron replete dams [6]. The impact of prenatal iron sta-
tus on FGF23 and Phos regulation and the corresponding impact on
bone health have not yet been investigated in humans. This may be es-
pecially relevant in populations with high rates of iron deﬁciency.
The aim of the current study was to investigate the inﬂuence of ma-
ternal iron status on circulating FGF23 and mineral homeostasis during
early life in rural Gambians; a population in which iron deﬁciency isthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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iron and Phos metabolism from 12 weeks (wk) to 2 years of age were
measured longitudinally in Gambian children born to mothers with
normal and low iron status during pregnancy.
2. Materials & methods
2.1. Participants
TheWest Kiang province of TheGambia,West Africa, is a subsistence
agricultural region with a high prevalence of iron deﬁciency anaemia
particularly among children and in pregnant women [13]. In addition,
elevated FGF23 concentrations have been detected in children with
rickets-like bone deformities in this area [14]. Participants were recruit-
ed from the MRC (Medical Research Council) Keneba ﬁeld station, as
part of the Early Nutrition and Immune Development trial of pregnant
women and their infants (ISRCTN49285450) in which women were
randomised to 4 intervention groups from b20 wk gestation [15]. All
groups received iron and folate (as per standard clinical care) with or
without additional multiple micronutrients and or protein energy
throughout pregnancy [15]. At 6 to 18months of age, the corresponding
children were then further randomised to a lipid-based nutritional sup-
plement, with or without additional multiple micronutrients forming a
total of 8 different supplement groups. Ethical approval was given by
The Gambian Government/MRC Unit Joint Ethics Committee and writ-
ten informed consent was obtained from participants or their parents/
guardians. The studywas conducted in accordancewith the Declaration
of Helsinki.
2.2. Sample collection and biochemical analysis
An overnight-fasted venous blood sample was collected in mothers
at “booking” (~14 wk of pregnancy) and at 20 and 30 wk of pregnancy
and in infants at 12, 24, 52, 78 and 104 wk of age. Blood samples were
collected into lithium heparin (LiHep) and EDTA-coated tubes.
Haemoglobin (Hb) was measured in maternal and infant whole blood
samples by haemoglobinometer (Medonic CA 530 Haematology
Analyser, Boule Medical AB, Stockholm, Sweden). Blood samples were
then separated by centrifugation after which the plasma was frozen at
−70 °C until analysis. Maternal LiHep samples and infant samples at
24wkwere analysed for ferritin (Ferr), iron (Fe), unbound iron binding
capacity (UIBC) and transferrin (Tf). Soluble transferrin receptor (sTfR)
and c-reactive protein (CRP) were measured in maternal samples only
(Cobas, Integra 400 Plus, Roche Diagnostics, Indiana, USA) at all time
points. Infant LiHep and EDTA plasma samples were transported on
dry ice to MRC Human Nutrition Research (HNR), Cambridge, UK, for
analysis of calcium (Ca), phosphate (Phos), albumin (Alb), magnesium
(Mg), total alkaline phosphatase (TALP), and cystatin C (Cys C) (Kone
Analyser 20i, Finland) and C-terminal and intact- ﬁbroblast growth
factor-23 (C-FGF23 & I-FGF23; Immutopics, CA, USA and Kainos, Japan
respectively) at all time points. Assay accuracy and precisionweremon-
itored across theworking range of the assays using kit controls supplied
by the manufacturer. In addition, an aliquot of a pooled plasma sample
was assayed in each batch to monitor possible drift over time. Intra and
inter- assay coefﬁcients of variation were b12% for I-FGF23, b7% for Cys
C, b4% for C-FGF23, and b2% for the remaining analytes.
2.3. Anthropometry and characteristics
Infant length, weight and head-circumference were measured at all
time points, using standard protocols and with regularly calibrated
equipment. Weight-for-age, length-for-age, weight-for-length and
head-circumference-for-age sex speciﬁc Z-scores were calculated
using WHO reference data [16].
All infants were breast-fed into the second year of life. The infants
were exclusively breastfed until a mean age of 5.3 months. This timingdid not differ signiﬁcantly by group 5.3 (1.3) vs. 5.4 (1.1) months
(P = 0.8) (Moore S.E, Personal Communication).
2.4. Sample selection for analysis
To detect a difference of ~67 RU/mL (or 0.75 of a standard deviation
based on existingGambiandata (not published)) in plasma C-FGF23 be-
tween two groups at β= 80% power α= 0.05 it was estimated that
each group needed 25 infants. Samples were selected on the basis of
maternal iron status at 20wk gestation (n=400). All maternal samples
with a CRP b5 mg/L and a measurement of Ferr and sTfR at 20 wk to-
gether with infants who had sufﬁcient EDTA plasma at all 5 time points
were eligible for selection (n=85).Womenwere then ranked by sTfR/
logFerr index and grouped into thosewith an sTfR (mg/L)/logFerr (μg/L)
N2.0 for low iron status [17] (LI, n= 25) and sTfR/logFerr b1.5 for nor-
mal iron status (NI, n=25) and the corresponding infant sampleswere
then analysed at all 5 time points. Therewas a similar distribution of the
8 supplement groups among the LI and NIwomen (data not shown).
2.5. Statistical analysis & calculations
Statistical analysis was performed using DataDesk 6.3.1 (Data De-
scription Inc., Ithaca, NY, USA) and all ﬁgures were drawn using
GraphPad Prism 5.0 (GraphPad Software, San Diego CA, USA). Data are
reported as mean and standard deviation (SD) for normally distributed
or geometric mean (+1SD,−1SD) for negatively skewed data. Hierar-
chical linear models, adjusted for participant ID (identiﬁcation code/
study number) and age (and infant weight-for-age Z-score for infant
biochemistry models only), were used to identify differences in vari-
ables over time. To identify overall group differences, the same hierar-
chical model was used with the addition of participant ID nested in
group. To identify speciﬁc timepoint differences by group an interaction
termbetween group and time pointwas included and Fisher's Least Sig-
niﬁcant Difference (LSD) post-hoc tests were reported. To determine
the extent of within individual tracking over time, hierarchical models
were used adjusting for age and participant ID and the F-ratio and P-
value reported for each variable. Backward step-wise elimination was
used to determine the predictors of plasma FGF23 concentration over
time. Glomerular ﬁltration rate (eGFR) was not a signiﬁcant predictor
of C-FGF23 concentration but was a signiﬁcant predictor of I-FGF23.
When included in the predictive models of C- and I-FGF23, eGFR made
no material difference to the relationships between Hb, I- and C-
FGF23 and sowas not included in themodels. Therewas a similar distri-
bution ofmales (M) and females (F) in the LI andNI children (F/M: LI=
10/15, NI = 13/12) and there was no sex difference in any of the
biochemical variables. There were sex differences in anthropometry
but thesewere accounted for with the calculation of age and sex adjust-
ed Z-scores and so sex was not included as a variable in the models.
P b 0.05 was considered as statistically signiﬁcant.
eGFR (mL/min) was estimated using the following equation
74:835
CysC ðmgL Þ
1:33 [18]. Calcium was corrected for albumin (Ca-corr; mmol/L)
by normalising to an albumin concentration of 36 g/L using a correction
factor 0.0167mmol Ca/g albumin [19]. This correction factor was calcu-
lated from the slope of the relationship between Ca and albumin using
local reference data [7].
3. Results
3.1. Maternal factors during pregnancy
At 20 wk of pregnancy the mean (SD) age of the mothers was 29.4
(7.0) years of age and height was 1.61 (0.06) metres, neither of which
differed signiﬁcantly between the groups (P= 0.9 and P= 0.4 respec-
tively).Mothers in the LI group tended to be lighter than themothers in
theNI group [53.0 (8.4) vs. 58.0 (11.8) kg, P=0.1] and their body mass
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difference was statistically signiﬁcant. The median (IQR) parity of the
womenwas 3 (4); sevenwere on their ﬁrst pregnancy. Number of preg-
nancies did not differ between groups (data not shown).
3.2. Maternal iron status during pregnancy
Haemoglobin (Hb) decreased and unsaturated iron binding capacity
(UIBC) and transferrin (Tf) increased signiﬁcantly from booking to
30 wk of pregnancy when looking at all of the mothers together (Fig.
1 and Table 1.).
The LImothers had signiﬁcantly lower Hb, Ferr, Fe and signiﬁcantly
higher soluble sTfR, UIBC and Tf compared with the NI group through-
out pregnancy (Fig. 1 and Table 1).
Forty-six percent of mothers had anaemia (Hb b 110 g/L) at booking
[LI: 64% vs. NI: 28%, P=0.01] which increased to 62% by 20wk [LI: 72%
vs.NI: 52%, P=0.1] and to 64% by 30 wk [LI: 80% vs.NI: 46%, P=0.01]
(See Table 3). All markers of iron status tracked signiﬁcantly within
individual mothers throughout pregnancy (See Table 1) (i.e. mothers
with low iron status remained low throughout gestation). The highest
within individual tracking in iron markers over time was seen in sTfR
and lowest in Fe.
3.3. Infant anthropometry from 12 to 104 wk of age
Weight-for-age, length-for-age, weight-for-length and head-
circumference-for-age Z-scores decreased signiﬁcantly from 12 to
104 wks. There were no group differences in length-for-age or head-
circumference-for-age Z-scores at any time point whereas weight-for-
age andweight-for-length Z-scorewere lower in the LI group compared
to the NI group at 12 and 104 wk. (Table 2). There was no difference in
gestational age at birth between groups [39.9 (1.04) vs. 39.9 (1.26) wk.,
P= 0.8].
3.4. Infant biochemistry from 12 to 104 wk of age
Circulating I-FGF23, Phos, Ca, TALP and Hb decreased and estimated
glomerular ﬁltration rate (eGFR) increased over time [overall mean
(SD) I-FGF23: 49.1 (13.1) to 34.3 (10.9) pg/mL, Phos: 1.86 (0.14) toFig. 1.Maternal biochemistry. Mothers selected based on soluble transferring receptor (sTfR m
circles), sTfR/log Ferr b 1.5 = Normal Iron (pink triangles). * indicates a signiﬁcant difference b1.68 (0.18) mmol/L, Ca: 2.63 (0.08) to 2.42 (0.16) mmol/L, TALP: 406
(133) to 318 (135) U/L, Hb: 107 (16) to 94 (16) g/L and eGFR: 59.9
(11.2) to 94.5 (23.4) mL/min all P ≤ 0.0001]. A drop was observed
from 12 to 52 wk after which time point Hb and I-FGF23 plateaued
from 52 to 104 wk (Fig. 2 and Table 4) whereas Ca remained elevated
until 24 wk after which time point it dropped to 104 wk (Fig. 2 and
Table 4). C-FGF23 did not change signiﬁcantly with age [402 (218) to
487 (502) RU/mL, P= 0.6].
3.5. Infant iron status at 24 wk of age
Infant iron stores at 24 wk tended to be lower in the LI group com-
pared to the NI group. This was particularly reﬂected by UIBC which
was signiﬁcantly higher in LI (P = 0.008) (Table 5.).
3.6. Maternal iron status and infant biochemistry
Infant circulating C-FGF23 concentration was signiﬁcantly differ-
ent by maternal iron status group (Fig. 2 and Table 4). C-FGF23 and
TALP were higher in LI compared with NI from 52 wk for C-FGF23
and from 24 wk for TALP. eGFR was signiﬁcantly lower in LI
compared to NI from 52 wk and Ca was signiﬁcantly lower in NI
compared with LI at 104 wk only. All other infant biochemistry did
not differ signiﬁcantly by group (Fig. 2 and Table 4). Although C-
FGF23 was elevated in the LI group compared to the NI group from
52 wk the group ∗ time point interaction term did not reach statisti-
cal signiﬁcance (P = 0.08).
3.7. Circulating infant FGF23 and Hb concentrations
Seventy percent of infants had anaemia (Hb b 110 g/L) at 12 wk
which increased over time to a peak of 97% at 78 wk (See Table 3) and
this was not signiﬁcantly different between group (Table 4).
After accounting for maternal group, C-FGF23 and infant Hb were
negatively associated with each other at 24, 52, 78 and 104 wk with ef-
fect sizes ranging from β (S.E.)−47.7 (9.9) %, r2= 35.58%, P b 0.0001 at
52 wk to β (S.E.)−33.4 (9.7) %, r2 = 25.3%, P=0.001 RU/mL at 78 wk.
Infant Hb was the strongest negative predictor of C-FGF23 concentra-
tion over time [β (S.E.) -20% (3%) RU/mL, P ≤ 0.0001without adjustmentg/L)/log ferritin (Ferr μg/L) index at 20 wk gestation: sTfR/log Ferr N 2.0 = Low Iron (blue
etween groups (P b 0.05) using least-squares post hoc tests as in Table 1.
Table 1
Maternal markers of iron status.
Maternal factors Week Mothers with low iron Mothers with normal iron Group difference P-value Overall change with time Within-individual tracking
(n= 25) (n= 25) Time point Overall β (S.E.) years P-value F-ratio P-value
Haemoglobin (g/L) Bk 107 (18) 118 (12) 0.0003 0.0006 −25.9 (7.1) 0.0004 4.2 0.0001
20 102 (14) 110 (9) 0.008
30 98 (15) 112 (13) 0.0001
Ferritin* (μg/L) Bk 8.7 (3.6, 21.1) 35.8 (10.8, 118.5) 0.0002 0.0001 −0.5 (0.5) 0.3 3.9 0.0001
20 6.6 (3.0, 14.4) 33.6 (20.1, 56.1) 0.0003
30 14.5 (8.0, 26.3) 20.9 (11.0, 39.7) 0.1
Iron (μmol/L) Bk 7.6 (4.3) 16.4 (6.7) 0.0003 0.0001 9.0 (6.0) 0.1 1.7 0.02
20 11.2 (8.6) 17.2 (5.2) 0.01
30 13.9 (10.4) 19.3 (12.8) 0.02
sTfR* (mg/L) Bk 5.9 (3.9, 9.1) 3.2 (2.5, 4.1) 0.0001 0.0001 0.23 (0.19) 0.2 8.7 0.0001
20 6.7 (4.8, 9.5) 2.9 (2.1, 3.9) 0.0001
30 6.0 (3.6, 9.9) 3.5 (2.5, 4.7) 0.0001
UIBCa (μmol/L) Bk 79.2 (16.0) 49.1 (13.9) 0.0001 0.0001 19.2 (9.9) 0.06 4.2 0.0001
20 79.7 (15.9) 52.1 (10.7) 0.0001
30 74.1 (20.3) 57.6 (17.6) 0.0001
Transferrin (g/L) Bk 3.8 (0.5) 3.0 (0.4) 0.0001 0.0001 1.11 (0.44) 0.01 2.4 0.0004
20 3.8 (0.9) 3.1 (0.4) 0.0001
30 3.8 (0.9) 3.5 (0.5) 0.07
Group deﬁned bymaternal soluble transferring receptor (sTfRmg/L)/log ferritin (Ferr μg/L) index at 20wk of gestation: sTfR/log Ferr N 2.0= Low Iron, sTfR/log Ferr b 1.5=Normal Iron.
Data aremean (SD) for normally distributed data and geometricmean (−1SD,+1SD) for skewed variables*. Overall group differencewas determined using hierarchical models with the
independent variable adjusted for time point, group and ID (ID nested in group). Time point difference between groupwas determined as for the overall group differencewith the addition
of a group ∗ time point interaction termwhere post-hoc tests were used to determine group differences at speciﬁc time points. Overall changewith timewas calculated using hierarchical
modelwith the independent variable adjusted for ID and age (years) and reported as theΒ-coefﬁcient (S.E.) in years for normally distributed independent variables and as a percentage for
skewed variables*. Within-individual tracking was determined with hierarchical models adjusting for age (years) and ID and the ID F-ratio and P-value are reported.
a UIBC is unbound iron binding capacity.
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nutritional status (infant weight-for-age Z-score)]. Including infant Hb
as a variable did not alter the magnitude of the group difference in C-
FGF23 over time [β (S.E.) from 15.8 (8.2) %, P = 0.05 to β (S.E.) 15.3
(7.4) % P = 0.04 without adjustment and from 18.1 (8.4) %, P = 0.04Table 2
Infant anthropometry.
Infant factor Week Lowmaternal iron Normal maternal iron
(n= 25) (n= 25)
Age (y) 12 0.25 (0.15) 0.25 (0.01)
24 0.47 (0.02) 0.46 (0.02)
52 1.00 (0.01) 1.00 (0.01)
78 1.51 (0.02) 1.50 (0.01)
104 2.00 (0.01) 2.00 (0.01)
Weight-for-height Z-score 12 −0.92 (1.50) −0.53 (1.11)
24 −0.71 (0.98) −0.67 (1.31)
52 −0.99 (1.02) −0.99 (1.40)
78 −0.95 (0.73) −0.83 (1.36)
104 −1.18 (0.78) −0.69 (1.36)
Length-for-age Z-score 12 −0.44 (1.38) −0.16 (1.47)
24 −0.44 (0.92) −0.26 (1.25)
52 −1.12 (1.05) −0.88 (1.02)
78 −1.35 (0.95) −1.03 (1.06)
104 −1.55 (0.79) −1.35 (1.21)
Weight-for-age Z-score 12 −1.06 (0.89) −0.58 (1.17)
24 −0.86 (1.03) −0.73 (1.23)
52 −1.28 (1.03) −1.15 (1.29)
78 −1.34 (0.85) −1.08 (1.18)
104 −1.67 (0.82) −1.19 (1.15)
Head-circumference-for-
age-Z-score
12 −0.50 (0.87) −0.27 (1.08)
24 −0.48 (0.90) −0.53 (1.13)
52 −0.77 (0.97) −1.07 (1.36)
78 −1.02 (1.75) −1.03 (1.32)
104 −0.97 (1.02) −1.15 (1.32)
Infants selected based onmaternal soluble transferring receptor (sTfRmg/L)/log ferritin (Ferr μ
Iron. Data are mean (SD). Overall group difference was determined using hierarchical models
Time point difference between group was determined as for the overall group difference with
determine group differences at speciﬁc time points. Overall change with time was calculated
and reported as the Β-coefﬁcient (S.E.) in years. Within-individual tracking was determined
are reported. “WHO Anthro” was used to determine Z-scores [16].to β (S.E.) 17.6 (7.7) % P= 0.03 with adjustment for infant nutritional
status].
Circulating I-FGF23was not signiﬁcantly associated with C-FGF23 or
Hb at any time point [C-FGF23:−0.4% (0.4%) RU/mL, P=0.3; Hb: 0.003
(0.01) g/L, P = 0.8 and C-FGF23: −0.5% (0.5%) RU/mL, P = 0.3; Hb:Group difference P-value Overall change with time Within-individual Tracking
Time point Overall β (S.E.) yrs P-value F-ratio P-value

































g/L) index at 20wk gestation: sTfR/log Ferr N 2.0= Low Iron, sTfR/log Ferr b 1.5=Normal
with the independent variable adjusted for time point, group and ID (ID nested in group).
the addition of a group ∗ time point interaction term where post-hoc tests were used to
using hierarchical model with the independent variable adjusted for ID and age (years)
with hierarchical models adjusting for age (years) and ID and the ID F-ratio and P-value
Fig. 2. Infant biochemistry. Infants selected based on maternal soluble transferring receptor (sTfR mg/L)/log ferritin (Ferr μg/L) index at 20 wk gestation: sTfR/log Ferr N 2.0 = Low Iron
(blue circles), sTfR/log Ferr b 1.5 = Normal Iron (pink triangles). * indicates a signiﬁcant difference between groups (P b 0.05) using least-squares post hoc tests as in Table 4.
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Phos was the strongest positive predictor of I-FGF23 [β (S.E.) 31.4
(3.9) pg/mL, P ≤ 0.0001 andβ (S.E.) 32.0 (3.9) pg/mL, P ≤ 0.0001] follow-
ed by eGFR [β (S.E.)−0.07 pg/mL, P b 0.05 and β (S.E.)−0.07 pg/mL,
P b 0.05].Table 3
Anaemia in pregnancy and infancy.
Time point % Anaemia haemoglobin b 110 g/L Chi square
P-value
All Low maternal iron Normal maternal iron
Mother
Booking 46.0 64.0 28.0 0.01
20 weeks 62.0 72.0 52.0 0.1
30 weeks 63.8 80.0 45.5 0.01
Infant
12 weeks 70.5 70.0 70.8 0.9
24 weeks 76.6 78.3 75.0 0.8
52 weeks 88.1 90.9 85.0 0.6
78 weeks 97.3 100.0 94.7 0.3
104 weeks 89.7 90.0 89.5 0.9
Percentage of mothers and infants with anaemia deﬁned by the World Health Organisa-
tion cut-off [33] at each time point split by maternal soluble transferring receptor (sTfR
mg/L)/log ferritin (Ferr μg/L)index at 20 wk gestation: sTfR/log Ferr N 2.0 = Low Iron,
sTfR/log Ferr b 1.5 = Normal Iron.3.8. Tracking of infant anthropometry and biochemistry over time
Allmarkers of anthropometry tracked signiﬁcantlywithin individual
infants across theﬁrst 2 years of life, particularlyweight andweight-for-
age Z-score (Table 2).
All biochemical markers corrected for weight-for-age Z-score, with
the exception of Mg and Ca-corrected for albumin, tracked signiﬁcantly
within individual infants with time (Table 4). Among those infant
biochemical markers with signiﬁcant tracking, the highest was seen
for TALP and C-FGF23.4. Discussion
Neonatal iron deﬁciency is known to have adverse effects on various
biological processes including neural development and cognitive per-
formance [20]. Recently, murine studies have shown the importance
of maternal iron status in pregnancy on offspring phosphate and
vitamin D metabolism via regulatory changes in skeletal FGF23 gene
expression leading to increased circulating concentrations of FGF23
[6]. This present study is the ﬁrst to investigate whether this is the
case in humans; speciﬁcally to address whether there is an effect of
maternal iron status during pregnancy on infant FGF23 and mineral
metabolism over the ﬁrst two years of life in a population with a high
prevalence of iron deﬁciency anaemia. In addition, this is the ﬁrst
study to investigate the longitudinal changes in FGF23 (C-terminal
Table 4
Infant biochemistry.
Factor Week Low maternal iron Normal maternal iron Group difference P-value Overall change with time Within-individual tracking
(n= 25) (n= 25) Time point Overall Β (S.E.) yrs P-value F-ratio P-value
Haemoglobin (g/L) 12 109 (18) 104 (11) 0.06 0.9 −0.6 (0.1) 0.0001 2.4 0.0001
24 103 (10) 104 (08) 0.8
52 95 (11) 99 (11) 0.3
78 90 (16) 97 (10) 0.07
104 95 (13) 94 (18) 0.6
Intact-ﬁbroblast growth
factor-23 (pg/mL)
12 47.4 (11.6) 50.8 (14.5) 0.2 0.5 −6.9 (1.0) 0.0001 4.2 0.0001
24 39.2 (10.2) 43.1 (10.7) 0.1
52 33.6 (8.9) 36.5 (14.2) 0.2
78 36.8 (8.4) 34.5 (10.9) 0.3
104 34.0 (11.3) 34.5 (10.7) 0.9
C-terminal ﬁbroblast growth
factor-23 (RU/mL)*
12 365 (212, 629) 347 (220, 548) 0.5 0.04 −3.2 (6.6) 0.6 4.8 0.0001
24 391 (207, 739) 325 (187, 563) 0.2
52 457 (160, 1307) 276 (145, 525) 0.003
78 395 (131, 1197) 255 (115, 564) 0.006
104 382 (133, 1101) 255 (114, 570) 0.008
Calcium (mmol/L) 12 2.66 (0.08) 2.62 (0.08) 0.3 0.1 −0.1 (0.02) 0.0001 4.5 0.04
24 2.67 (0.11) 2.62 (0.12) 0.2
52 2.55(0.09) 2.52 (0.16) 0.4
78 2.47 (0.17) 2.43 (0.25) 0.3
104 2.45 (0.11) 2.38 (0.21) 0.04
Phosphate (mmol/L) 12 1.84 (0.12) 1.88 (0.15) 0.6 0.4 −0.1 (0.02) 0.00001 2.3 0.0001
24 1.77 (0.20) 1.80 (0.17) 0.5
52 1.68 (0.14) 1.75 (0.22) 0.5
78 1.69 (0.17) 1.65 (0.22) 0.8
104 1.66 (0.19) 1.72 (0.16) 0.1
Magnesium (mmol/L) 12 0.86 (0.06) 0.87 (0.05) 0.9 0.8 −0.03 (0.01) 0.02 1.0 0.41
24 0.88 (0.05) 0.87 (0.12) 0.7
52 0.87 (0.05) 0.87 (0.09) 0.8
78 0.84 (0.13) 0.84 (0.12) 0.9
104 0.85 (0.07) 0.83 (0.12) 0.7
Total alkaline phosphatase
(U/L)
12 420.8 (165.9) 392.4 (93.6) 0.2 0.1 −31.3 (9.6) 0.001 6.4 0.0001
24 373.6 (153.9) 306.8 (77.9) 0.001
52 263.7 (81.3) 256.7 (83.3) 0.6
78 310.2 (106.7) 258.7 (66.9) 0.002
104 340.9 (162.0) 289.9 (93.7) 0.001
Cystatin C (mg/L) 12 1.22 (0.24) 1.19 (0.14) 0.4 0.1 −0.17 (0.02) 0.0001 4.0 0.0001
24 1.05 (0.16) 1.07 (0.22) 0.9
52 1.00 (0.18) 0.88 (0.22) 0.008
78 0.93 (0.17) 0.81 (0.16) 0.003
104 0.89 (0.16) 0.84 (0.16) 0.1
Estimated glomerular
ﬁltration rate (mL/min)
12 59.3 (12.8) 59.8 (10.1) 0.5 0.03 18.3 (2.2) 0.0001 4.0 0.0001
24 72.0 (17.5) 73.8 (24.2) 0.4
52 78.5 (21.0) 89.2 (22.8) 0.005
78 89.3 (25.7) 101.1 (23.3) 0.006
104 93.5 (26.8) 97.0 (20.7) 0.04
Albumin (g/L) 12 32.85 (2.72) 33.56 (2.93) 0.8 0.6 0.9 (0.3) 0.009 2.6 0.0001
24 36.72 (2.69) 36.62 (2.81) 0.8
52 36.88 (2.95) 37.06 (3.85) 0.9
78 35.84 (2.23) 35.43 (3.51) 0.3
104 35.43 (3.31) 35.24 (4.49) 0.3
Calcium-corrected for
albumin (mmol/L)
12 2.71 (0.07) 2.66 (0.06) 0.2 0.01 −0.15 (0.01) 0.0001 1.2 0.2
24 2.66 (0.09) 2.61 (0.11) 0.1
52 2.54 (0.06) 2.49 (0.15) 0.3
78 2.47 (0.16) 2.44 (0.21) 0.4
104 2.46 (0.09) 2.39 (0.16) 0.06
Infants selected based onmaternal soluble transferring receptor (sTfRmg/L)/log ferritin (Ferr μg/L) index at 20wk gestation: sTfR/log Ferr N 2.0= Low Iron, sTfR/log Ferr b 1.5=Normal
Iron. Data aremean (SD) for normally distributeddata and geometricmean (−1SD,+1SD) for skewedvariables*. Overall group differencewas determinedusing hierarchicalmodelswith
the independent variable adjusted for time point, infant weight-for-age Z-score, group and ID (ID nested in group). Time point difference between groupwas determined as for the overall
group differencewith the addition of a group ∗ time point interaction termwhere post-hoc testswere used to determine group differences at speciﬁc time points. Overall changewith time
was calculated using hierarchical model with the independent variable adjusted for infant weight-for-age Z-score, ID and age (years) and reported as the Β-coefﬁcient (S.E.) in years for
normally distributed independent variables and as a percentage for skewed variables*. Within-individual tracking was determined with hierarchical models adjusting for age (years),
infant weight-for-age Z-score and ID and the ID F-ratio and P-value are reported.
6 V.S. Braithwaite et al. / Bone 83 (2016) 1–8and I-) in conjunction with mineral metabolites and glomerular ﬁltra-
tion rate in full term infants through to childhood [21].
We showed thatmaternal Hb andmarkers of iron status track across
pregnancy; womenwith low iron status continued to have low iron sta-
tus until late gestation. In this sub-cohort of women selected by antena-
tal iron status, overall the anaemia rate in the mothers increased from
46% at booking to 64% by 30 wk of pregnancy despite supplementation.Similarly, the anaemia rate in the children increased from 70% of chil-
dren at 12 wk to 90% at 2 years of age, and tracking of Hb concentration,
as well as other biochemical and anthropometric markers, was seen
across infancy. Individual tracking of variables was particularly strong
for C-FGF23, TALP, weight-for-age and length-for-age Z-scores across
infancy. As growth faltering is common during the ﬁrst two years of
life in rural Gambia [22] it was unsurprising that weight-for-age and
Table 5
Infant iron status markers at 24 wk of age.
Analyte at 24 weeks All Low maternal iron Normal maternal iron P-value
Haemoglobin (g/L) 103 (9) 103 (10) 104 (9) 0.7
Ferritin*(μg/L) 26.7(8.7, 81.3) 12.9 (6.9, 69.1) 32.2 (11.1, 94.0) 0.2
Iron (μmol/L) 6.3 (2.3) 5.9 (2.4) 6.7 (2.1) 0.2
Transferrin (g/L) 2.9 (0.6) 3.1 (0.5) 2.9 (0.6) 0.1
Unbound iron binding capacity (μmol/L) 62.4 (15.3) 68.3 (15.8) 56.8 (12.5) 0.008
⁎ Data are mean (SD) for normally distributed data and geometric mean (−1SD, +1SD) for skewed variables.
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children in the LI group had even lower weight-for-age Z-scores com-
pared to those in the NI group.
74% of all C-FGF23 concentrations measurements were well above
the commonly accepted upper limit of normal of 125 RU/mL [8] and
the extremely high measures of C-FGF23 (from 1000 to 3800 RU/mL)
were seen only in children with anaemia. C-FGF23 concentration did
not change signiﬁcantly with age throughout the ﬁrst 2 years of life in
these children. The main ﬁnding from this study is that C-FGF23 was
higher in the children born from mothers with a low sTfR/Ferr index
(LI) diverging sometime between 6 and 12 months of life and lasting
until at least 2 years of age compared to those in the NI group. In addi-
tion TALP was also higher in LI from 24 wk of age compared to the NI
group. TALP when elevated is a marker of metabolic bone disease and
is elevated in children with rickets [23]. The increased TALP concentra-
tions in the LI group may be indicating that poor iron status has a
negative inﬂuence on bone health, possibly mediated through its asso-
ciation with elevated FGF23 production.
Interestingly, I-FGF23 and Phos followed similar trajectories to each
other throughout infancy; a sharp decrease over theﬁrst year and then a
plateau during the 2nd yearwhile eGFR in theNI group had an opposite
trajectory; a sharp increase over the ﬁrst year and then a plateau during
the 2nd year. I-FGF23, rather than eGFR, was the strongest predictor of
Phos over time, after accounting for maternal iron status. It is unknown
whether circulating FGF23 changes in women during pregnancy al-
though it has been shown to increase in pregnant mice [24]. Additional
mice studies have demonstrated that the foetus produces its own FGF23
and that circulating maternal FGF23 does not cross the placenta [25].
Furthermore, as the half-life of FGF23 is less than an hour [26] the infant
circulating FGF23 concentrations measured in our study reﬂects infant
rather than maternally derived FGF23.
Our study provides evidence in support of the ﬁnding of
Clinkenbeard et al., inmice of in utero effects of iron on FGF23 regulation
[6]. The Clinkenbeard study involved feeding pregnantmice a normal or
low iron diet from 14 days of pregnancy through to weaning (21 days
after birth). Their study showed cross-sectional differences at 21 days
of life in the offspring of the iron-depleted dams; including a higher C-
FGF23 and I-FGF23 and lower Phos concentration compared with off-
spring of the iron-replete dams.Whether or not these group differences
were present before or after 21 days of life was not investigated. In our
study in humanswe detected group differences in C-FGF23, but not in I-
FGF23 or Phos, depending on maternal iron status in pregnancy which
appeared from around 6 months of life and remained to at least
2 years of age. This ﬁts in with the timing of cessation of exclusive
breastfeedingwhich occurred at amean age of 5.4months in these chil-
dren which did not differ signiﬁcantly between groups. The ﬁndings of
similar concentrations of C-FGF23 in the two groups for the ﬁrst 6
months of life may suggest that both groups of infants were born with
sufﬁcient iron stores for the ﬁrst 6 months of life. Thereafter, those in-
fants born to mothers with low iron status may more rapidly become
iron depleted. Alternatively, the LI children may have been exposed to
a similar iron-poor environment as their mothers after the introduction
of solid foods (~6 months of age) compared to the NI group. However,
this is a less likely explanation as the markers of iron status suggest
that the LI childrenwere showing signs of poor iron status by 6 months
of age.There are two commercial assays available tomeasure human FGF23
in blood. The intact assay detects epitopes which cross the cleavage site
of FGF23 and therefore detects only the intact protein whereas the C-
terminal assay detects epitopes within the C-terminal of the protein
and thus detects both the intact protein and cleaved C-terminal frag-
ments. The intact protein is thought to be phosphaturic whereas there
is conﬂicting evidence with regards to the biological activity of the C-
and N- terminal fragments [27,28].
The pathway bywhich low iron increases C-FGF23 expression is not
clear but growing evidence points towards an involvement of the
hypoxia-inducible-factor (HIF) pathway, activated by anaemia andhyp-
oxia, in the increase in FGF23 gene expression [5,6]. This results in an in-
crease of production and of intra- and extracellular degradations of the
FGF23 hormone leading to increases in circulating C-FGF23 concentra-
tion but unchanged or slightly elevated concentrations of I-FGF23.
Whether or not there are additional direct effects of iron on the down-
stream processing and catabolism of FGF23 protein is unclear. If tissue
hypoxia is the driver of osteocyte FGF23 gene expression rather than
iron deﬁciency per se these ﬁndings may have implications for a num-
ber of disease states of chronic hypoxia such as cystic ﬁbrosis (CF) and
chronic pulmonary disorder (COPD) as well as complications during
childbirth. Both CF and COPD patients are known to have compromised
bone health and a study in COPD patients has shown that Phos and
FGF23 metabolism is altered [29]. Elevation of FGF23 gene expression
as a result of chronic hypoxia is a plausible explanation of theseﬁndings.
An additional ﬁnding was the consistently and signiﬁcantly lower
infant eGFR in children in the LI group compared to the NI group
appearing after 24 wk of age suggesting a potential role of iron in neo-
natal renal development. In support of this possibility, a study in rats
showed that iron deﬁcient neonatal rats had abnormal renal develop-
ment including lower glomerular density, area and count, despite simi-
lar growth rates to iron replete neonates [30].
Limitations of the study include that the mothers and infants were
participants of a supplementation trial [15]. Although all women re-
ceived the same amount of iron and folic acid throughout pregnancy
(60 mg of Fe and 400 μg of folic acid daily) and there was an equal dis-
tribution of all supplement groups between LI andNI, no account could
bemadeof possible supplement effects. In addition,more frequent sam-
pling in the children and additional markers of iron status, hypoxia and
markers of vitamin Dmetabolism would have provided further mecha-
nistic insights. We can assume from previous studies in this population
that women and children in this present study had good vitamin D sta-
tus, as determined by 25-hydroxyvitamin D concentration [31,32].
However, we do not know whether or not FGF23-driven group differ-
ences in 1,25-dihydroxyvitamin D were present because they were
not measured in this study. The tendency towards a lower BMI in LI
mothers compared with the NI mothers raises the possibility that
poor overall nutrition during pregnancy rather than speciﬁcally iron
deﬁciency may be responsible for the FGF23 effects in infancy. Only
a placebo-controlled iron supplementation trial during pregnancy
would be able to answer this question deﬁnitely.
In conclusion, this study suggests that poor maternal iron status
leads to higher infant C-FGF23 and TALP concentrations in human in-
fants and young children but had no signiﬁcant effect on infant I-
FGF23. These ﬁndings further highlight the likely public health impor-
tance of preventing iron deﬁciency during pregnancy. Whether or not
8 V.S. Braithwaite et al. / Bone 83 (2016) 1–8children who are born to iron deﬁcient mothers have persistently high
concentrations of these metabolites and are more likely to be at risk of
impaired bone development and pre-disposed to rickets requires
further research.
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